Log in
ASX:KZA

Kazia Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.40
MA: A$0.40▼
A$0.40
52-Week Range N/A
Volume47,736 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops therapies for a range of oncology indications. Its lead product is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway that is in Phase II clinical trials to treat glioblastoma multiforme. The company is also developing TRX-E-002-1 (Cantrixil), a third-generation benzopyran molecule, which is in Phase I clinical trials to treat ovarian cancer. It has collaboration agreements with The University of York, The Children's Cancer Institute Australia, The Mater Institute in Queensland, the University of Boston, and St Jude Children's Research Hospital, as well as Dana-Farber Cancer Institute. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.48 out of 5 stars


Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:KZA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.kaziatherapeutics.com
Phone61 2 9472 4101

Debt

Debt-to-Equity RatioN/A
Current Ratio2.10
Quick Ratio1.97

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$988,110.00
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow4.49
Book ValueA$0.15 per share
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive KZA News and Ratings via Email

Sign-up to receive the latest news and ratings for KZA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kazia Therapeutics (ASX:KZA) Frequently Asked Questions

Who are some of Kazia Therapeutics' key competitors?

Some companies that are related to Kazia Therapeutics include Abattis Bioceuticals (ATTBF), ABcann Global (ABCN), ABZENA/PAR VTG FPD 0.002 (ABZA), Acrux (ACR), Actinogen Medical (ACW), Adalta (1AD), Admedus (AHZ), Almirall (LBTSF), Amarantus Bioscience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR), Antibe Therapeutics (VBIZF), Aortech International (RUA), Apotheca Biosciences (CBDC) and Arno Therapeutics (ARNI).
View all competitors.

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 46)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill, Company Sec. (Age 60)
  • Kym Robins, Director of Marketing & Communications
  • Dr. Justine R. Stehn B.Sc (Hons), Ph.D., Director of ATM Program

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the ASX under the ticker symbol "KZA."

How big of a company is Kazia Therapeutics?

Kazia Therapeutics has a market capitalization of $0.00 and generates $988,110.00 in revenue each year.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

How can I contact Kazia Therapeutics?

The company can be reached via phone at 61 2 9472 4101.

This page was last updated on 9/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.